Shield Therapeutics (LSE:STX) FCF Yield % : -235.17 (As of May. 01, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Shield Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Shield Therapeutics's Trailing 12-Month Free Cash Flow is £-24.83 Mil, and Market Cap is £10.56 Mil. Therefore, Shield Therapeutics's FCF Yield % for today is -235.17%.

The historical rank and industry rank for Shield Therapeutics's FCF Yield % or its related term are showing as below:

LSE:STX' s FCF Yield % Range Over the Past 10 Years
Min: -610.12 Med: -8.43 Max: -1.42
Current: -235.17

During the past 9 years, the highest FCF Yield % of Shield Therapeutics was -1.42%. The lowest was -610.12%. And the median was -8.43%.

LSE:STX's FCF Yield % is ranked worse than
96.95% of 1083 companies
in the Drug Manufacturers industry
Industry Median: -0.62 vs LSE:STX: -235.17

Shield Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was -497.00%.

Shield Therapeutics FCF Yield % Historical Data

The historical data trend for Shield Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shield Therapeutics FCF Yield % Chart

Shield Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Yield %

Get a 7-Day Free Trial

-8.99

-2.60

-1.91

-21.16

-105.03

Shield Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
FCF Yield %	Get a 7-Day Free Trial													-14.58	-25.45	-196.34	-35.97	-89.51

Competitive Comparison of Shield Therapeutics's FCF Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics's FCF Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's FCF Yield % falls into.

Shield Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Shield Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-19.207	/	18.286854
	=	-105.03%

Shield Therapeutics's annualized FCF Yield % for the quarter that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-21.54	*	2	/	48.12993
	=	-89.51%

Shield Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Shield Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Shield Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shield Therapeutics (LSE:STX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shield Therapeutics PLC (LSE:STX) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

SHIEF:USA 1JS:Germany

Address

Northern Design Centre, Baltic Business Quarter, Gateshead Quays, Newcastle, GBR, NE8 3DF

Website

https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments are based on key products including Accrufer/Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available, and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from Feraccru segment.